Ketalux - Ketamine Therapy EducationKetalux - Independent Ketamine Education
Regulatory Tracker

The December 31, 2026 Telemedicine Deadline: What It Means for Ketamine Patients

A plain-English explainer of the federal telemedicine rule that at-home ketamine programs rely on, and what could change on January 1, 2027.

Written by: Ira ZootMedical review status: Not yet clinically reviewed.Last updated: November 7, 2026Evidence: Primary federal sources

This page has been written and edited by the publisher. It has not been reviewed by a licensed clinician.

Quick answer
What happens to telehealth ketamine prescribing after December 31, 2026?
A temporary federal rule lets DEA-registered clinicians prescribe controlled medications, including ketamine, by video without first seeing the patient in person. That rule runs through December 31, 2026. A permanent replacement has been drafted but, as of this update, has not been published. What happens on January 1, 2027 depends on what federal agencies publish before then.

Why this matters for ketamine

Ketamine is a Schedule III controlled substance. Under the Ryan Haight Act of 2008, prescribing a controlled substance over the internet generally requires at least one in-person medical evaluation first. Since 2020, a series of temporary rules has waived that requirement. At-home ketamine programs that start care entirely by video rely on that waiver.

What the current rule says

The fourth temporary extension, published by the DEA and HHS in the Federal Register on December 31, 2025 (90 FR 61301), applies from January 1 through December 31, 2026 [1]. It allows a DEA-registered practitioner to prescribe Schedule II–V medications by telemedicine without an in-person evaluation when:

  • the prescription is for a legitimate medical purpose in the usual course of practice;
  • it follows a real-time audio-video visit (an "interactive telecommunications system");
  • the practitioner is properly registered with the DEA; and
  • it meets all other federal prescription requirements.

State laws apply on top of this, and some are stricter.

What is pending

In January 2025 the DEA proposed a permanent framework, "Special Registrations for Telemedicine and Limited State Telemedicine Registrations" [2]. As proposed, it would create special DEA registrations for telemedicine prescribers, require some telehealth platforms to register, and add identity-verification, prescription-monitoring and recordkeeping requirements. A final version has been under review at the White House Office of Information and Regulatory Affairs since August 2026 [3]. Its text is not public, so nobody outside government knows yet what the final rule will require.

Three ways this could go

If…What it likely means for patients
A final rule is published before January 1, 2027Programs must meet the new registration requirements. Some may pause, change, or add in-person steps while they comply.
Agencies issue another temporary extensionTelehealth prescribing continues much as it does now, for the length of the extension.
Neither happensThe in-person evaluation requirement returns. New telehealth-only patients would generally need an in-person visit before a controlled-substance prescription.

Ketalux does not predict which of these will happen. We will update this page when anything is published in the Federal Register.

What is not affected

Spravato (esketamine) is already given only in certified healthcare settings with on-site monitoring under an FDA safety program, so it does not depend on telehealth prescribing rules. See esketamine (Spravato).

Questions to ask your program now

  • How are you preparing for January 1, 2027, under each of the three scenarios?
  • Will I need an in-person evaluation, and where would it happen?
  • If my prescriptions are interrupted, what is the plan for continuity of care?
  • Who do I contact if I have a problem during a gap?
What not to do
Do not stockpile medication, change your dose, or obtain ketamine from any source outside a licensed prescriber and pharmacy. Talk to your prescriber about any concern about continuity. The FDA has separately warned that compounded ketamine used at home without monitoring carries risks including sedation, dissociation, raised blood pressure and breathing problems [4]. If you are in crisis, call or text 988 (US).
Not legal or medical advice
This page explains public federal rules. Your clinician and program can tell you how they apply to you. Related reading: Regulatory Tracker and at-home ketamine programs.

Frequently asked questions

When does telehealth prescribing of ketamine without an in-person visit end?+

The current temporary federal rule runs through December 31, 2026. What applies from January 1, 2027 depends on whether federal agencies publish a final permanent rule or another extension before then.

Will I need an in-person visit for ketamine in 2027?+

It depends on what is published before January 1, 2027, and on your state's law. If neither a final rule nor an extension is published, the general requirement of an in-person evaluation before prescribing a controlled substance by telemedicine returns. Ask your prescriber how they are preparing.

Does the DEA deadline affect Spravato (esketamine)?+

Spravato is already given only in certified healthcare settings with on-site monitoring under an FDA safety program, so it does not depend on telehealth prescribing rules.

References

  1. Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications (90 FR 61301). Drug Enforcement Administration and Department of Health and Human Services, Federal Register · 2025 Regulatory
  2. Special Registrations for Telemedicine and Limited State Telemedicine Registrations (proposed rule). Drug Enforcement Administration, Federal Register · 2025 Regulatory
  3. Regulatory review record for RIN 1117-AB40. Office of Information and Regulatory Affairs (reginfo.gov) Regulatory
  4. FDA warns patients and health care providers about potential risks associated with compounded ketamine. U.S. Food and Drug Administration · 2023 Regulatory
About the author

Publisher and editor of Ketalux, based in Chicago, Illinois. Ira is a ketamine therapy patient, not a clinician. This is editorial review, not medical review: Ira is not a licensed clinician and does not provide diagnosis or medical care. Ketalux does not accept compensation from providers in exchange for favorable editorial coverage, evidence ratings, recommendations, patient referrals, or organic provider ranking. Read the full publisher disclosure →

Educational use only. The content on this page is provided for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Ketamine and related therapies carry risks and are appropriate only under qualified medical supervision. Always consult a licensed healthcare professional about your individual situation. Information may change as research evolves.